Establishing a continuum of care between HIV prevention trials and public healthcare systems: The MIRA Standard of Care program

Abstract

Background The ability of researchers to provide sustainable care to individuals who acquire HIV during participation in HIV prevention trials has rapidly expanded along with national treatment options. The Methods for Improving Reproductive Health in Africa (MIRA) trial (2003—2006), a phase III multi-site randomized controlled trial, measured the effectiveness of the diaphragm used with Replens^® lubricant gel in preventing heterosexual acquisition of HIV among women in Zimbabwe and South Africa. The MIRA Standard of Care program, which started towards the end of the trial period and continued for 5 months after trial closeout, enabled women who acquired HIV during the trial to receive additional counseling and clinical care and facilitated links to long-term HIV-related care and treatment from public health facilities.

Purpose To describe eligible participants’ uptake of these optional services and evaluate the program’s strengths and limitations.

Methods All women who acquired HIV during their MIRA participation were re-contacted and invited to return to the study clinics for additional care and referrals. Sites reported monthly statistics of uptake of services.

Results From start to end, 185 of 323 (57%) HIV-positive participants accepted additional care; 81 (25%) could not be relocated. 142 (44%) women received referrals to government healthcare facilities and 90 (28%) enrolled in wellness/ treatment programs. Fifty-seven (18%) declined further care, but reasons for doing so were not recorded systematically.

Limitations The program began after most participants had exited from the MIRA trial and required re-contacting women, resulting in difficulty in locating some participants.

Conclusions In the future, care for participants who seroconvert should be offered at the trial onset and fully integrated into clinical trials to avoid losing these participants for further care. More research is needed to identify and understand perceived barriers to establishing a continuum of care between clinical trials and public sector health facilities. Clinical Trials 2010; 7: 256—264. http:// ctj.sagepub.com

Get full access to this article

View all access options for this article.

References

Joint United Nations Program on HIV/AIDS (UNAIDS) and World Health Organization. 2009 AIDS Epidemic Update . UNAIDS, Geneva, 2009.

Joint United Nations Program on HIV/AIDS (UNAIDS), World Health Organization. Sub-Saharan Africa AIDS Epidemic Update Regional Survey. UNAIDS/WHO, Geneva, 2008.

Mahomva A. , Greby S. , Dube S. , et al. HIV prevalence and trends from data in Zimbabwe, 1997-2004. Sex Transm Infect 2006; Suppl 1: i42-7.

Gregson S. , Garnett GP , Nyamukapa CA , et al. HIV decline associated with behavior change in eastern Zimbabwe . Science 2006; 5761: 664-6.

Human Sciences Research Council. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2008 . HSRC Press, Cape Town, 2009.

UNAIDS / WHO Working Group on Global HIV/AIDS and STI Surveillance Epidemiological Fact Sheet on HIV and AIDS: South Africa (2008 Update). Geneva , 2009.

Unaids / Who Working Group on Global HIV / AIDS and STI Surveillance. Epidemiological Fact Sheet on HIV and AIDS: Zimbabwe (2008 Update). Geneva, 2009.

Slack C. , Stoble M. , Milford C. , et al. Provision of HIV treatment in HIV preventive vaccine trials: a developing country perspective. Soc Sci Med 2005; 6: 1197-208.

UNAIDS Global Reference Group on HIV / AIDS and Human Rights. Issue Paper: Human Rights and Ethical Perspectives on HIV Vaccine Trials. Geneva, 2003.

10.

Treating people with intercurrent infection in HIV prevention trials. Report from a WHO/UNAIDS consultation, Geneva 17-18th July 2003. AIDS 2004; 15: W1-12.

11.

Macklin R. Standard of care: an evolution in ethical thinking. Lancet 2008; 9635: 284-5.

12.

Stolberg SG In Global Battle on AIDS, Bush Creates Legacy . The New York Times. January 5, 2008. Available at: http://www.nytimes.com/2008/01/05/washington/05aids.html?_r=1&oref=slogin (accessed 28 February 2010).

13.

Belsky L. , Richardson HS Medical researchers’ ancillary clinical care responsibilities . BMJ 2004; 328: 1494-6.

14.

Joint United Nations Program on HIV/AIDS (UNAIDS), World Health Organization. Ethical Considerations in Biomedical HIV Prevention Trials. UNAIDS/ WHO , Geneva, 2007.

15.

Padian NS , van der Straten A. , Ramjee G. , et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007; 9583: 251-61.

16.

Ramjee G. , van der Straten A. , Chipato T. , et al. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One 2008; 3: e3488.

17.

Hyder AA , Merritt MW Ancillary care for public health research in developing countries . JAMA 2009; 302: 429-31.

18.

Participants in the 2006 Georgetown University Workshop on the Ancillary-Care Obligations of Medical Researchers Working in Developing Countries. The ancillary care obligations of medical researchers working in developing countries. PLoS Med 2008; 5: 709-13.

19.

Global Campaign for Microbicides. Consultation on operationalising access to HIV treatment and care . Meeting Report, Washington, DC, 19-20th June 2008.

20.

Posse M. , Meheus F. , van Asten H. , et al. Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health 2008 ; 7: 904-13.

21.

World Health Organization. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. 2007.